KR20200016608A - The health food composition for regulating weight - Google Patents
The health food composition for regulating weight Download PDFInfo
- Publication number
- KR20200016608A KR20200016608A KR1020180091905A KR20180091905A KR20200016608A KR 20200016608 A KR20200016608 A KR 20200016608A KR 1020180091905 A KR1020180091905 A KR 1020180091905A KR 20180091905 A KR20180091905 A KR 20180091905A KR 20200016608 A KR20200016608 A KR 20200016608A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- health food
- composition
- obesity
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 235000013402 health food Nutrition 0.000 title claims abstract description 26
- 230000001105 regulatory effect Effects 0.000 title 1
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 22
- 239000001259 polydextrose Substances 0.000 claims abstract description 22
- 229940035035 polydextrose Drugs 0.000 claims abstract description 22
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 20
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 20
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 102000008186 Collagen Human genes 0.000 claims abstract description 18
- 108010035532 Collagen Proteins 0.000 claims abstract description 18
- 229920001436 collagen Polymers 0.000 claims abstract description 18
- 239000000835 fiber Substances 0.000 claims abstract description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 18
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 17
- 229930091371 Fructose Natural products 0.000 claims abstract description 16
- 239000005715 Fructose Substances 0.000 claims abstract description 16
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 16
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 16
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 claims abstract description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 9
- 239000004376 Sucralose Substances 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 9
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 9
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 9
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 9
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 9
- 239000001527 calcium lactate Substances 0.000 claims abstract description 9
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 9
- 239000000679 carrageenan Substances 0.000 claims abstract description 9
- 229920001525 carrageenan Polymers 0.000 claims abstract description 9
- 229940113118 carrageenan Drugs 0.000 claims abstract description 9
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 9
- 229960000304 folic acid Drugs 0.000 claims abstract description 9
- 235000019152 folic acid Nutrition 0.000 claims abstract description 9
- 239000011724 folic acid Substances 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940107702 grapefruit seed extract Drugs 0.000 claims abstract description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 9
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 9
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002477 riboflavin Drugs 0.000 claims abstract description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 9
- 235000019408 sucralose Nutrition 0.000 claims abstract description 9
- 229960003495 thiamine Drugs 0.000 claims abstract description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 9
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 9
- 239000011719 vitamin A Substances 0.000 claims abstract description 9
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 9
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 9
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 9
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 229940045997 vitamin a Drugs 0.000 claims abstract description 9
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 9
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 9
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 9
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 8
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 8
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 8
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229940007115 shark cartilage extract Drugs 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 238000004260 weight control Methods 0.000 claims abstract description 6
- 239000000686 essence Substances 0.000 claims abstract description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 241000723343 Cichorium Species 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 10
- 235000015205 orange juice Nutrition 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 8
- 235000005282 vitamin D3 Nutrition 0.000 claims description 8
- 239000011647 vitamin D3 Substances 0.000 claims description 8
- 229940021056 vitamin d3 Drugs 0.000 claims description 8
- 229940050549 fiber Drugs 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229960002737 fructose Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 abstract description 27
- 235000020824 obesity Nutrition 0.000 abstract description 27
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000002075 main ingredient Substances 0.000 abstract description 6
- 239000012141 concentrate Substances 0.000 abstract description 5
- 208000004930 Fatty Liver Diseases 0.000 abstract description 4
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 4
- 208000010706 fatty liver disease Diseases 0.000 abstract description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 4
- -1 vitamic D3 Substances 0.000 abstract description 3
- 244000298479 Cichorium intybus Species 0.000 abstract 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002303 citric acid monohydrate Drugs 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000019577 caloric intake Nutrition 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000579 abdominal fat Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000011325 biochemical measurement Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/28—Substances of animal origin, e.g. gelatin or collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 체중조절용 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition for weight control.
국민경제가 급속도로 발전하고 산업화가 급속히 진행됨에 따라 에너지 함량이 높은 인스턴트 가공식품을 많이 섭취하고 운동량이 적어지면서 비만이 국민건강을 심각하게 위협하는 요인이 되고 있다. 비만은 거북하고 아름답지 못한 외모로 보는 사람에게 좋지 않은 이미지를 주고 활동에도 불편을 줄 뿐아니라, 비만인은 정상인에 비하여 당뇨병, 동맥경화증, 고혈압, 심장병, 간장병, 담석증, 통풍, 신장병 등의 발생율과 수술시 위험성이 높아 대체로 단명한다고 보고되고 있다. 따라서, 비만은 중년을 넘어선 사람에게는 생명에 관한 문제이며, 젊은 여성에게는 특히 미용상의 이유로 심각하게 고려되고 있다.As the national economy develops rapidly and industrialization proceeds rapidly, obesity is a serious threat to national health, as it consumes a lot of instant processed foods with high energy content and reduces exercise. Obesity not only gives a bad image and uncomfortable to the viewer, but also makes people uncomfortable with activities.In addition, obesity is associated with diabetes, arteriosclerosis, hypertension, heart disease, liver disease, gallstones, gout, and kidney disease. It is reported that the risk of surgery is high and generally short-lived. Thus, obesity is a life issue for those who are over the middle age, and seriously considered for young women, especially for cosmetic reasons.
현재 비만증 치료제로서 식욕억제제, 체열발생제, 이뇨제 등이 사용되고 있으나 장기 복용시 혈압상승, 의존성 설사, 변비, 불면, 불안 등의 부작용을 나타내므로 비만을 억제하기 위해서 오랜 세월 동안 안전성과 생리기능이 검증된 여러 식품소재의 이용에 대한 관심이 높아지고 있다. 현재 비만인을 위한 건강식품으로 식이섬유, 생약재, 여러 식품소재를 함유하는 제품들이 개발되었으나, 식사량을 줄이고 이 제품들을 섭취할 경우 여러 영양소의 부족으로 인한 부작용으로 정상적인 생활이 어렵고, 복용을 중단하면 빠르게 다시 비만해지는 단점이 있는 것으로 알려져 있다.Appetite suppressants, heat generators, and diuretics are currently used as treatments for obesity, but they have side effects such as blood pressure rise, dependent diarrhea, constipation, insomnia, anxiety, etc. There is a growing interest in the use of various food materials. Currently, products containing dietary fiber, herbal medicines, and various food ingredients have been developed as a health food for obese people.However, if you reduce the amount of meals and consume these products, normal life is difficult due to the side effects of various nutrients. It is known that there is a disadvantage of being obese again.
본 발명자는 비만 및 이와 관련된 질환을 효율적으로 예방 및 억제할 수 있는 건강식품으로서, 이를 섭취하며 식사량을 줄이거나 이를 식사대용으로 섭취하더라도 정상적인 사회생활에 지장을 주지 않고 효율적으로 체지방을 감소시킬 수 있으며, 상기 체중조절용 건강식품의 복용을 중단하더라도 일정기간 내에는 다시 비만의 상태로 되돌아가지 않는 비만조절용 건강식품을 개발하고자 각종 생약재, 기능성 식품소재, 비타민 및 미네랄 등을 여러 비율로 배합하는 실험을 거듭하고, 그 효과를 실험으로 입증하여 본 발명을 완성하였다.The present invention is a health food that can effectively prevent and suppress obesity and related diseases, even if ingested, reducing the amount of meal or eating it as a meal substitute can effectively reduce body fat without affecting normal social life, In order to develop obesity control health foods that do not return to obesity within a certain period of time even if the user stops taking the weight control health foods, experiments are conducted in which various herbal ingredients, functional food materials, vitamins and minerals are mixed in various ratios. And the effect was proved experimentally and completed this invention.
본 발명에 의하면, 폴리덱스트로스, 콜라겐, 치커리화이바, 말토덱스트린, 액상과당, 프락토올리고당, 오렌지농축과즙에 여러 보조성분을 첨가함으로서 정상생활을 하는데 필요한 최소의 하루열량을 충족하여 부작용이 최소화된 체중조절용 건강식품 조성물 및 그의 제조방법이 제공된다.According to the present invention, by adding various auxiliary ingredients to polydextrose, collagen, chicory fiber, maltodextrin, liquid fructose, fructooligosaccharide, and orange juice concentrate, it meets the minimum daily calories required for normal life, thereby minimizing side effects. Health food compositions and methods for making the same are provided.
폴리덱스트로스, 콜라겐, 치커리화이바, 말토덱스트린, 액상과당, 프락토올리고당, 오렌지농축과즙(65Brix)를 주성분으로 하고, 글루콘산칼슘, 함수구연산, 비타민C, 젖산칼슘, 가르시니아캄보지아추출물, L-카르니틴, 상어연골추출분말, 글루콘산아연, 오렌지에센스, 수크랄로스, 나이아신, 젖산철, 비타민A, 비타민B1, 비타민B2, 비타민B6염산염, 비타민D3, 비타민E, 엽산, 자몽종자추출물, 카라기난을 보조성분으로 함유하는 본 발명의 건강식품 조성물은 상기 실험예들의 결과에서 나타난 바와 같이 비만은 물론 이와 관련된 질환인 지방간, 동맥경화, 그리고 당뇨병을 효율적으로 억제해 준다.Mainly composed of polydextrose, collagen, chicory fiber, maltodextrin, liquid fructose, fructooligosaccharide, orange concentrated fruit juice (65 Brix), calcium gluconate, hydrous citric acid, vitamin C, calcium lactate, garcinia cambogia extract, L-carnitine, shark Cartilage Extract Powder, Zinc Gluconate, Orange Essence, Sucralose, Niacin, Iron Lactate, Vitamin A, Vitamin B1, Vitamin B2, Vitamin B6 Hydrochloride, Vitamin D3, Vitamin E, Folic Acid, Grapefruit Seed Extract, Carrageenan The health food composition of the present invention effectively suppresses obesity as well as related diseases, fatty liver, arteriosclerosis, and diabetes, as shown in the results of the experimental examples.
본 발명에 의하면, 폴리덱스트로스, 콜라겐, 치커리화이바, 말토덱스트린, 액상과당, 프락토올리고당, 오렌지농축과즙에 여러 보조성분을 첨가함으로서 정상생활을 하는데 필요한 최소의 하루열량을 충족하여 부작용이 최소화된 체중조절용 건강식품 조성물 및 그의 제조방법이 제공된다.According to the present invention, by adding various auxiliary ingredients to polydextrose, collagen, chicory fiber, maltodextrin, liquid fructose, fructooligosaccharide, and orange juice concentrate, it meets the minimum daily calories required for normal life, thereby minimizing side effects. Health food compositions and methods for making the same are provided.
본 발명의 식품소재 중 폴리덱스트로스는 포도당, 솔비톨, 구연산을 원료로 포도당을 무작위적으로 결합시킨 평균분자량 1,500의 수용성 식이섬유이며, 전분과 같은 소화성 다당류의 대체품으로 가공식품 용도로 널리 사용되고 있다.Among the food materials of the present invention, polydextrose is a water-soluble dietary fiber having an average molecular weight of 1,500 randomly combined with glucose as a raw material of glucose, sorbitol and citric acid, and is widely used for processed foods as an alternative to digestible polysaccharides such as starch.
치커리화이바는 치커리로부터 만든 식이섬유로 다이어트 보조식품으로 널리 사용되고 있다.Chicory fiber is a dietary fiber made from chicory and is widely used as a dietary supplement.
프락토올리고당은 설탕에 프락토오스 전이효소를 반응시켜 얻은 당류로 난소화성으로 위장, 소장 등에서 흡수되기 어려워 에너지 섭취를 제한하며, 포만감을 증진시키는 효과가 있는 것으로 알려져 있다.Fructooligosaccharides are sugars obtained by reacting fructose transferase with sugar, which are indigestible and difficult to be absorbed in the stomach and small intestine, limiting energy intake and enhancing satiety.
말토덱스트린 역시 난소화성으로 당뇨치료 등에 사용되고 있으며 본 발명에서 에너지 섭취를 최소화하게 한다.Maltodextrin is also used for the treatment of diabetes due to indigestion and to minimize energy intake in the present invention.
콜라겐은 섬유성단백질군으로 연골세포, 관절, 근섬유의 생성하며, 피부보습 및 피부탄력을 유지하는 역할을 한다. 특히 다이어트시 콜라겐이 빠져나가 피부탄력성의 저하가 나타나게 되므로, 본 발명의 조성물에 반드시 포함되어야 한다. 음식물을 통해 콜라겐 섭취가 가능할 수 있지만 콜라겐 성분은 우리 체내에서 잘 협착되지 않는 메카니즘을 가지고 있어 그 효과가 미미하다. 그러므로 본 발명에서는 콜라겐을 오렌지 농축과즙 등과 함께 알맞게 배합되어 협착이 잘 되게 한다.Collagen is a group of fibrous proteins that produces chondrocytes, joints, and muscle fibers, and plays a role in maintaining skin moisture and skin elasticity. In particular, since collagen is released during the diet and the skin elasticity is lowered, it must be included in the composition of the present invention. It may be possible to consume collagen through food, but collagen has little effect because it has a mechanism that does not narrow well in our body. Therefore, in the present invention, collagen is suitably blended with orange juice concentrate and the like to make narrowing well.
액상과당은 포도당을 효소에 의해 이성화하여 과당과 포도당이 혼합된 액당이다. 감미도가 설탕과 거의 같고 포도당의 부드러운 맛과 과당의 상쾌한 맛이 조화되어 본 발명에서 식사대용의 에너지원과 미감을 위해 적정비율로 배합된다.Liquid fructose is a liquid sugar obtained by mixing glucose with glucose by isomerizing glucose with an enzyme. The sweetness is almost the same as that of sugar, and the soft taste of glucose and the refreshing taste of fructose are harmonized, so that the present invention is formulated in an appropriate ratio for energy source and aesthetic sense of meal replacement.
본 발명에 따르는 체중조절용 건강식품에 배합되는 주성분의 양은 중량기준으로 폴리덱스트로스 15-25%, 콜라겐 15-25%, 치커리화이바 3-6%, 말토덱스트린 10-15%, 액상과당 15-25%, 프락토올리고당 15-20%, 오렌지농축과즙(65Brix) 4-8%가 바람직하다.The amount of the main ingredient formulated in the weight control health food according to the present invention is 15-25% polydextrose, collagen 15-25%, chicory fiber 3-6%, maltodextrin 10-15%, liquid fructose 15-25%, 15-20% fructooligosaccharide and 4-8% orange juice (65 Brix) are preferred.
상기 건강식품의 보조성분으로는 글루콘산칼슘, 함수구연산, 비타민C, 젖산칼슘, 가르시니아캄보지아추출물, L-카르니틴, 상어연골추출분말, 글루콘산아연, 오렌지에센스, 수크랄로스, 나이아신, 젖산철, 비타민A, 비타민B1, 비타민B2, 비타민B6염산염, 비타민D3, 비타민E, 엽산, 자몽종자추출물, 카라기난 등을 적정량 포함할 수 있으며, 바람직하게는 건강식품 조성물 총 중량의 8-12%의 양으로 포함되는 것이 좋다.Supplementary ingredients of the health foods include calcium gluconate, hydrous citric acid, vitamin C, calcium lactate, garcinia cambogia extract, L-carnitine, shark cartilage extract powder, zinc gluconate, orange essence, sucralose, niacin, iron lactate, vitamin A , Vitamin B1, vitamin B2, vitamin B6 hydrochloride, vitamin D3, vitamin E, folic acid, grapefruit seed extract, carrageenan and the like may be included in an appropriate amount, preferably contained in an amount of 8-12% of the total weight of the health food composition It is good.
본 발명의 건강식품 조성물에 함유되는 주성분 및 보조성분은 모두 식품재료 및 식품 및 의약첨가물로 사용되어 온 것이므로, 복용 도는 섭취시 인체에 대한 안전성이 우수하다.Since both the main ingredient and the auxiliary ingredient contained in the health food composition of the present invention have been used as food ingredients and food and pharmaceutical additives, the dosage is excellent for the human safety when ingested.
식사대용으로 본 발명의 상기 배합비율에 의한 조성물은 정상 생활을 하면서 최소의 열량만을 섭취케하여 비만조절을 효과적으로 할 수 있게 해준다.The composition according to the compounding ratio of the present invention as a meal replacement allows to control obesity effectively by ingesting only a minimum amount of calories while living a normal life.
본 발명에 따른 조성물은 통상의 방법에 따라 분말화하거나 추출하여 캡슐, 정제, 과립 등의 형태로 제형화할 수 있으며, 젤 타입의 액상음료로 제조하는 것이 식사대용으로 먹기에 가장 바람직하다.The composition according to the present invention may be formulated in the form of capsules, tablets, granules, etc. by powdering or extracting according to a conventional method, and it is most preferable to prepare a gel-type liquid beverage for eating as a meal.
본 발명에 따르는 액상 건강식품 조성물의 제조방법은 (1) 배합탱크에 정제수(50℃)를 투입하고, 액상과당, 말토덱스트린, 상어연골추출물분말, 치커리화이바, 폴리덱스트로스, 비타민C, 오렌지농축과즙, 콜라겐, 글루콘산칼슘, 젖산칼슘, 프락토올리고당, 가르시니아캄보지아추출물, 글루콘산아연, 수크랄로스, 젖산철은 Hopper를 통해 투입한 후 용해시키는 단계; (2) 상기 제1용액이 완전히 용해되었으면 L-카르니틴, 비타민A, 비타민B1, 비타민B2, 비타민B6염산염, 비타민D3, 비타민E, 엽산, 나이아신, 자몽종자추출물을 Hopper를 통해 투입한 후 충분히 용해시키는 단계; (3) 상기 제2용액이 완전히 용해되었으면 카라기난과 구연산을 혼합 후 정수(20℃)에 믹서기를 이용해 용해시킨 후 Hopper를 통해 투입한 후 다시 충분히 용해시키는 단계; (4) 상기 제3용액에 오렌지에센스를 투입하고 5분간 교반하는 단계로 구성된다. 이때 정제수와 조성물의 비율은 80-85% : 15-20% 이 되도록 하고, 조성물의 배합비율은 상기와 같은 주성분과 보조성분의 배합비율에 의한다. 조성물의 각 성분의 열에 약한 정도와 용해도 등의 조건에 따라 용해순서가 다르도록 한 것이다.Method for producing a liquid health food composition according to the present invention (1) to the purified water (50 ℃) in the mixing tank, liquid fructose, maltodextrin, shark cartilage extract powder, chicory fiber, polydextrose, vitamin C, orange juice concentrate, Collagen, calcium gluconate, calcium lactate, fructooligosaccharide, garcinia cambogia extract, zinc gluconate, sucralose, iron lactate are dissolved through a Hopper; (2) When the first solution is completely dissolved, L-carnitine, vitamin A, vitamin B1, vitamin B2, vitamin B6 hydrochloride, vitamin D3, vitamin E, folic acid, niacin, and grapefruit seed extract are introduced through the Hopper and then completely dissolved. Making a step; (3) if the second solution is completely dissolved, after mixing carrageenan and citric acid, dissolving it in a purified water (20 ° C.) using a blender, and then injecting it through a Hopper to fully dissolve again; (4) It is composed of the step of adding an orange essence to the third solution and stirring for 5 minutes. At this time, the ratio of purified water and the composition is 80-85%: 15-20%, and the blending ratio of the composition is based on the blending ratio of the main and auxiliary components as described above. The order of dissolution varies depending on conditions such as weakness and solubility in heat of each component of the composition.
이하, 실시예에 의해 본 발명을 보다 상세히 설명하지만 본 발명이 이들 실시예에 국한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
실시예1Example 1 . 본 발명에 따르는 건강식품 조성물 제조. Health food composition preparation according to the present invention
폴리덱스트로스 18%, 콜라겐 20%, 치커리화이바 5%, 말토덱스트린 12%, 액상과당 19%, 프락토올리고당 19%, 오렌지농축과즙(65Brix) 7%비율로 혼합하고 상기 혼합물의 양의 4배의 증류수를 넣고 혼합하여 제조하였다.18% polydextrose, 20% collagen, 5% chicory fiber, maltodextrin 12%, 19% liquid fructose, 19% fructooligosaccharide, 7% orange concentrated fruit juice (65 Brix) and distilled water 4 times the amount of the mixture Was prepared by mixing.
실시예2Example 2 . 본 발명에 따르는 건강식품 조성물 제조. Health food composition preparation according to the present invention
폴리덱스트로스 17.55%, 콜라겐 18.72%, 치커리화이바 3.28%, 말토덱스트린 11.7%, 액상과당 17.55%, 프락토올리고당 17.55%, 오렌지농축과즙(65Brix) 5.85%, 글루콘산칼슘 0.234%, 함수구연산0.585%, 비타민C 0.99%, 젖산칼슘 1.76%, 가르시니아캄보지아추출물 0.35%, L-카르니틴 0.02%, 상어연골추출분말 0.12%, 글루콘산아연 0.2%, 오렌지에센스0.585%, 수크랄로스 0.029%, 나이아신 0.028%, 젖산철 0.028%, 비타민A 0.023%, 비타민B1 0.013%, 비타민B2 0.013%, 비타민B6염산염 0.013%, 비타민D3 0.002%, 비타민E 0.038%, 엽산0.002%, 자몽종자추출물0.117%, 카라기난 2.63%비율로 혼합하고 상기 혼합물의 양의 4배의 증류수를 넣고 혼합하여 제조하였다.Polydextrose 17.55%, collagen 18.72%, chicory fiber 3.28%, maltodextrin 11.7%, liquid fructose 17.55%, fructooligosaccharide 17.55%, orange juice (65Brix) 5.85%, calcium gluconate 0.234%, hydrous citric acid 0.585%, vitamin C 0.99%, calcium lactate 1.76%, garcinia cambogia extract 0.35%, L-carnitine 0.02%, shark cartilage extraction powder 0.12%, zinc gluconate 0.2%, orange essence 0.585%, sucralose 0.029%, niacin 0.028%, iron lactate 0.028% %, Vitamin A 0.023%, Vitamin B1 0.013%, Vitamin B2 0.013%, Vitamin B6 hydrochloride 0.013%, Vitamin D3 0.002%, Vitamin E 0.038%, Folic acid 0.002%, Grapefruit seed extract 0.117%, Carrageenan 2.63% Four times the amount of the mixture was added to distilled water was prepared by mixing.
실시예3Example 3 . 본 발명에 따르는 액상 건강식품 제조. Liquid health food preparation according to the present invention
(1) 배합탱크에 800L의 정제수(50℃)를 투입하고, 액상과당 75kg, 말토덱스트린 50kg, 상어연골추출물분말 0.5kg, 치커리화이바 14kg, 폴리덱스트로스, 비타민C, 오렌지농축과즙, 콜라겐, 글루콘산칼슘, 젖산칼슘, 프락토올리고당, 가르시니아캄보지아추출물, 글루콘산아연, 수크랄로스, 젖산철은 Hopper를 통해 투입한 후 충분히 용해시키는 단계;(1) 800L of purified water (50 ° C) was added to the mixing tank, 75 kg of liquid fructose, 50 kg of maltodextrin, 0.5 kg of shark cartilage extract powder, 14 kg of chicory fiber, polydextrose, vitamin C, orange juice, collagen, calcium gluconate , Calcium lactate, fructooligosaccharide, garcinia cambogia extract, zinc gluconate, sucralose, iron lactate are added through a Hopper and then fully dissolved;
(2) 상기 제1용액이 완전히 용해되었으면 L-카르니틴, 비타민A, 비타민B1, 비타민B2, 비타민B6염산염, 비타민D3, 비타민E, 엽산, 나이아신, 자몽종자추출물을 Hopper를 통해 투입한 후 충분히 용해시키는 단계; (3) 상기 제2용액이 완전히 용해되었으면 카라기난과 구연산을 혼합 후 정수(20℃)에 믹서기를 이용해 용해시킨 후 Hopper를 통해 투입한 후 다시 충분히 용해시키는 단계; (4) 탱크 안 총량이 2,480L가 되도록 정제수를 투입하고 충분히 용해시키는 단계; (5) 탱크 안 총량이 2,500L가 되도록 정제수와 오렌지에센스를 투입하고 5분간 교반하는 단계로 구성된다.(2) When the first solution is completely dissolved, L-carnitine, vitamin A, vitamin B1, vitamin B2, vitamin B6 hydrochloride, vitamin D3, vitamin E, folic acid, niacin, and grapefruit seed extract are introduced through the Hopper and then completely dissolved. Making a step; (3) if the second solution is completely dissolved, after mixing carrageenan and citric acid, dissolving it in a purified water (20 ° C.) using a blender, and then injecting it through a Hopper to fully dissolve again; (4) adding purified water and dissolving sufficiently so that the total amount in a tank becomes 2,480L; (5) It consists of adding purified water and orange essence and stirring for 5 minutes so that the total volume in the tank is 2,500L.
이 때 액상 건강식품 2500L 안의 조성물의 기준함량(L)은 액상과당 75, 말토덱스트린 50, 상어연골추출물분말 0.5, 치커리화이바 14, 폴리덱스트로스 75, 비타민C 4.25, 오렌지농축과즙 25, 콜라겐 80, 글루콘산칼슘 1, 젖산칼슘 7.5, 프락토올리고당 75, 가르시니아캄보지아추출물 1.5, 글루콘산아연0.875, 수크랄로스 0.125, 젖산철 0.125, L-카르니틴 0.0825, 비타민A 0.1, 비타민B1 0.055, 비타민B2 0.055, 비타민B6염산염 0.055, 비타민D3 0.00825, 비타민E 0.16250, 엽산0.00825, 나이아신 0.125, 자몽종자추출물 0.5, 카라기난 11.25, 함수구연산 2.5, 오렌지에센스 2.5가 되도록 한다.At this time, the standard content (L) of the composition in the liquid health food 2500L is liquid fructose 75, maltodextrin 50, shark cartilage extract powder 0.5, chicory fiber 14, polydextrose 75, vitamin C 4.25, orange concentrated fruit juice 25, collagen 80, gluconic acid Calcium 1, calcium lactate 7.5, fructooligosaccharide 75, garcinia cambogia extract 1.5, zinc gluconate 0.875, sucralose 0.125, iron lactate 0.125, L-carnitine 0.0825, vitamin A 0.1, vitamin B1 0.055, vitamin B2 0.055, vitamin B6 hydrochloride 0.055 , Vitamin D3 0.00825, vitamin E 0.16250, folic acid 0.00825, niacin 0.125, grapefruit seed extract 0.5, carrageenan 11.25, hydrous citric acid 2.5, orange essence 2.5.
(실험예1) 비만증 억제효과 실험(동물실험)Experimental Example 1 Obesity Inhibitory Effect Experiment (Animal Experiment)
본 실험에 사용된 동물은 웅성 스프래그-다울리(Sprague-Dawley)계 흰 쥐였다. 4주령의 쥐를 구입하여 1주간 시판 펠렛(pellet)시료를 급여한 뒤 10마리씩 군을 나누었다. 정상대조군은 계속 펠렛사료만 주고 나머지 모든 군은 펠렛사료와 함께 사람에게 가장 흔히 발생하는 비만유형과 가장 가까운 비만증을 유발한다고 알려진 카페테리아 다이어트(cafeteria diet)를 급여하였으며, 모든 사료와 물을 자유섭취시켰다. 카페테리아 다이어트를 2주간 급여한 후, 본 발명의 건강식품 조성물의 주원료 중 폴리덱스트로스, 치커리화이바, 프락토올리고당, 말토덱스트린 각각과, 건강식품 주원료인 폴리덱스트로스(식이섬유), 콜라겐, 치커리화이바, 말토덱스트린, 액상과당, 프락토올리고당, 오렌지농축과즙의 혼합물에 증류수를 넣고 혼합하여 0.4ml가 되게 하여 하루 2회 각각 경구투여하였으며, 대조군은 동 부피의 생리식염수를 경구투여하였다. 6주간 카페테리아 다이어트를 급여하면서 시료를 경구투여하였는데, 시료의 투여량은 사람의 1일 사용량과 사람과 쥐의 체중비율로부터 환산하였다. 카페테리아 다이어트로 쿠키, 비스켓, 땅콩, 치즈, 감자칩, 아몬드, 소세지 및 햄을 급여하였다. The animals used in this experiment were male Sprague-Dawley rats. Four-week-old rats were purchased and fed with a pellet sample for one week, then divided into groups of ten. The normal control group continued to feed pellets and all the other groups fed the pelleter diet with the cafeteria diet, which is known to cause obesity closest to the most common types of obesity in humans, and freed all feed and water. . After the diet for two weeks, the main ingredients of the health food composition of the present invention, polydextrose, chicory fiber, fructooligosaccharide, maltodextrin and each of the main food ingredients, polydextrose (dietary fiber), collagen, chicory fiber, maltodextrin, Distilled water was added to a mixture of liquid fructose, fructooligosaccharide and orange concentrated fruit juice to make 0.4 ml and orally administered twice a day, and the control group was orally administered the same volume of physiological saline solution. The samples were orally administered for 6 weeks with a cafeteria diet. The cafeteria diet was fed cookies, biscuits, peanuts, cheese, potato chips, almonds, sausages and ham.
시료를 6주간 경구투여한 후 심장에서 혈액을 채취하고, 간, 신장 지방조직(pe rirenal fat pad) 및 정소상체지방조직(epididymal fat pad)을 잘라내어 무게를 측정하였다.After oral administration of the sample for 6 weeks, blood was collected from the heart, and liver, kidney fat tissue (pe rirenal fat pad) and epididymal fat tissue (epididymal fat pad) were cut out and weighed.
화학분석간 중성지질을 분석하기 위하여 간의 지질을 추출한 뒤 효소법으로 중성지질을 정량하였다. 혈청의 총 콜레스테롤, HDL-콜레스테롤 및 포도당 함량은 드라이 케미스트리 시스템(dry chemistry system, 일본 Daiichi사 제품)을 이용하여 분석하였다.To analyze neutral lipids between chemical analyzes, lipid lipids were extracted, and neutral lipids were quantified by enzyme method. Serum total cholesterol, HDL-cholesterol and glucose content were analyzed using a dry chemistry system (Daiichi, Japan).
실험결과Experiment result
실험예1에 따르는 건강식품 주성분의 비만 억제기능 조사 결과를 다음 표1에 나타내었다. 비만대조군에 비하여, 주성분 중 폴리덱스트로스, 치커리화이바, 프락토올리고당이 통계적으로 유의성있게 체중 증가량을 6.3~7.3% 감소시켰으며 열량섭취 9.3~11.4% 감소시켰다. 폴리덱스트로스 투여군 및 치커리화이바 투여군 및 프락토올리고당 투여군에서 총 열량섭취 중 펠렛사료로 섭취된 열량비율이 65%, 69%, 58%로 높아졌으나, 특히 이들을 전부 포함하는 실시예1의 본 발명의 조성물 투여군에서 80%까지 높아짐을 알 수 있다. 이는 폴리덱스트로스가 치커리화이바 및 프락토올리고당과 함께 사람의 비만을 유발하는 주요 요인 중 하나인 카페테리아 다이어트의 섭취를 억제하여 열량 섭취를 감소시켰음을 알 수 있는 것으로, 본 발명의 조성물이 부작용을 지닌 비만 치료용 식욕억제제 대신 활용될 수 있는 좋은 비만인용 식품소재임을 알 수 있는 것이다.Obesity inhibition function of the health food main ingredient according to Experimental Example 1 is shown in Table 1 below. Compared with the obese control group, polydextrose, chicoryfiber, and fructooligosaccharides significantly reduced weight gain by 6.3 ~ 7.3% and calorie intake by 9.3 ~ 11.4%. Although the caloric ratio ingested as pellet feed during the total calorie intake was increased to 65%, 69%, and 58% in the polydextrose-treated group, the chicory fiber-administered group, and the fructooligosaccharide-treated group, in particular, the composition-administered group of Example 1 containing all of them It can be seen that up to 80%. It can be seen that polydextrose, along with chicory fiber and fructooligosaccharide, reduced calorie intake by inhibiting the intake of the cafeteria diet, which is one of the main factors causing obesity in humans. It can be seen that it is a good food material for obesity that can be used instead of an appetite suppressant.
또한, 폴리덱스트로스, 치커리화이바, 프락토올리고당은 복부지방의 축적을 억제하였으며, 치커리화이바와 프락토올리고당이 간의 중성지방 축적을 억제하였다. 치커리화이바와 말토덱스트린이 혈당농도를 감소시켰고, 폴리덱스트로스, 치커리화이바는 비만대조군에 비하여 동맥경화 위험수준을 감소시켰다. 또한, 본 발명의 7종의 주성분을 함께 급여한 경우는 체중증가량이 비만대조군에 비하여 15% 감소하여 폴리덱스트로스, 치커리화이바, 프락토올리고당 각각만을 급여한 경우보다 체중 증가가 더욱 크게 억제되었으며 다른 모든 측정치도 한 성분만 급여한 경우보다 낮아져서 간의 중성지방함량, 동맥경화 위험지수 및 혈당농도가 정상 대조군과 같은 수준으로 되었다.In addition, polydextrose, chicoryfiber, and fructooligosaccharide inhibited the accumulation of abdominal fat, and chicory fiber and fructooligosaccharide inhibited the accumulation of triglycerides in the liver. Chicoryfiba and maltodextrin decreased blood glucose levels, and polydextrose and chicoryfiba reduced the risk of atherosclerosis compared to the obese control group. In addition, when the seven main ingredients of the present invention was fed together, the weight gain was reduced by 15% compared to the obese control group, and the weight gain was further suppressed more than the case where only the polydextrose, chicory fiber, and fructooligosaccharide were respectively fed, and all other measures In addition, the level of triglyceride content, arteriosclerosis risk index and blood glucose level were lower than those of the normal control group.
이상의 결과는 폴리덱스트로스, 치커리화이바, 프락토올리고당이 모두 각각 체중증가 및 복부지방 축적을 억제하여 비만증을 억제할 수 있음을 알려준다. 뿐만아니라 상기 세 성분이 적정비율로 포함된 본 발명의 조성물의 비만증 및 이에 관련된 성인병 억제효과는 더욱 상승하여 더욱 효율적으로 비만증 및 이와 관련된 질환인 지방간, 동맥경화, 그리고 당뇨병을 억제할 수 있음을 보여주고 있다.The above results indicate that polydextrose, chicoryfiba, and fructooligosaccharide can all suppress weight gain and abdominal fat by inhibiting weight gain and abdominal fat accumulation, respectively. In addition, the anti-obesity and related diseases of the composition of the present invention containing the three components in an appropriate ratio is further increased to show that obesity and associated diseases such as fatty liver, arteriosclerosis, and diabetes can be more effectively suppressed. Giving.
(표1) 비만증억제효과1 (Table 1) Anti-obesity effect 1
1 평균치± SE(표준오차), 1군당 10마리. P<0.05 1 Mean ± SE (standard error), 10 per group. P <0.05
2 도살전 15일간 측정 2 measured 15 days before slaughter
3 (총콜레스테롤-HDL콜레스테롤)/HDL콜레스테롤 3 (Total Cholesterol-HDL Cholesterol) / HDL Cholesterol
4 열량섭취중 펠렛사료로 섭취된 비율 4 intake of pellets during calorie intake
또한, 본 발명의 실시예2,3에서 제조된 조성물의 비만증 억제기능 조사결과는 표2에 나타내었다. 본 발명의 조성물이 부여된 모든 군이 비만대조군에 비하여 유의성있게 체중증가, 열량섭취, 복부지방축적 및 간의 중성지방 축적을 억제하였고, 동맥경화 위험지수와 혈당농도도 감소시켰다. 이러한 결과는 각 실시예에서 제조된 조성물들이 비만증 및 이와 관련된 질환인 지방간. 동맥경화 그리고 당뇨병을 효율적으로 억제할 수 있음을 입증하는 것이다.In addition, the results of the antiobesity inhibitory investigation of the compositions prepared in Examples 2 and 3 of the present invention are shown in Table 2. All groups given the composition of the present invention significantly inhibited weight gain, calorie intake, abdominal fat accumulation, and hepatic triglyceride accumulation, and reduced atherosclerosis risk index and blood glucose level, compared to the obese control group. These results indicate that the compositions prepared in each example are fatty liver, in which obesity and related diseases. It proves that it can effectively suppress arteriosclerosis and diabetes.
무엇보다도 실시예2,3의 조성물을 섭취하는 경우 비만대조군과 같은 카페테리아 다이어트 시료를 급여하였음에도 불구하고 체중증가나 체지방 등의 요인이 비만증을 유발하지 않는 정상대조군과 필적할 정도로 억제되었음을 알 수 있다.Above all, ingesting the compositions of Examples 2 and 3, despite feeding a cafeteria diet sample such as the obesity control group, it can be seen that factors such as weight gain and body fat were suppressed to be comparable to the normal control group which does not cause obesity.
(표2) 비만증 억제효과 실험1 (Table 2) Experiment 1 for inhibiting obesity
1 평균치± SE(표준오차), 1군당 10마리. (P<0.05) 1 Mean ± SE (standard error), 10 per group. (P <0.05)
2 도살전 15일간 측정 2 measured 15 days before slaughter
3 (총콜레스테롤-HDL콜레스테롤)/HDL콜레스테롤 3 (Total Cholesterol-HDL Cholesterol) / HDL Cholesterol
4 열량섭취중 펠렛사료로 섭취된 비율 4 intake of pellets during calorie intake
(실험예2) 비만증 억제효과 실험(임상실험)Experimental Example 2 Obesity Inhibitory Effect Experiment (Clinical Experiment)
표준체중(kg) = (신장(cm)-100) x 0.9Standard weight (kg) = (height (cm) -100) x 0.9
비만도(%) = (실제체중-표준체중)/(표준체중) x 100Obesity degree (%) = (actual weight-standard weight) / (standard weight) x 100
위의 두 공식에 의하여 계산된 비만도 30% 이상의 성인남녀 각 5인에게 이침과 점심시간 전에 실시예3에 따르는 액상 건강식품을 각 200ml 씩 섭취시켰다. 이렇게 28알간 섭취시킨 후, 체형, 임상 및 생화학적 측정을 하여 섭취 전과 비교한 결과를 표3에 나타내었다. 28일간 섭취시킨 결과 체중이 평균 4.14kg 감소하고 체지방이 22% 감소하였다. 또한, 허리둘레, 상박둘레, 엉덩이 둘레 및 혈청 총 콜레스테롤과 LDL-콜레스테롤 농도가 섭취 전에 비해 통계적으로 유의하게 감소하였으며 섭취 중단 후 28일간 체중증가량은 평균 0.72kg에 불과하였다. 이러한 결과는 본 발명의 체중조절용 건강식품 조성물이 사람의 비만을 매우 효과적으로 억제할 수 있으며, 섭취를 중단한 경우 빠르게 체중이 증가하는 요요현상도 나타나지 않음을 입증하는 것이다.Obesity degree calculated by the above two formulas was ingested 200ml each of the liquid health food according to Example 3 to each of five adult men and women more than 30% before and after acupuncture. After taking 28 tablets in this way, the body, clinical and biochemical measurements were compared with the results before ingestion in Table 3. Ingestion for 28 days resulted in an average weight loss of 4.14 kg and a 22% reduction in body fat. In addition, waist circumference, upper arm circumference, hip circumference and serum total cholesterol and LDL-cholesterol concentrations were significantly decreased compared to before ingestion. These results prove that the health food composition for weight control of the present invention can effectively suppress human obesity, and when the intake is stopped, the yoyo phenomenon of rapidly increasing weight does not appear.
(표3) 다이어트 기간중 체형, 임상 및 생화학적 측정치의 변화1 Table 3 Changes in body shape, clinical and biochemical measurements during the diet period 1
1평균치± SE, P<0.05평 1 mean ± SE, P <0.05 pyeong
Claims (3)
Polydextrose 15-25%, collagen 15-25%, chicory fiber 3-6%, maltodextrin 10-15%, liquid fructose 15-25%, fructooligosaccharide 15-20%, orange juice juice (65 Brix) 4-8 Health food composition for weight control containing as a main component.
According to claim 1, calcium gluconate, hydrous citric acid, vitamin C, calcium lactate, garcinia cambogia extract, L-carnitine, shark cartilage extract powder, zinc gluconate, orange essence, sucralose, niacin, iron lactate, vitamin A, vitamin B1, vitamin B2, vitamin B6 hydrochloride, vitamin D3, vitamin E, folic acid, grapefruit seed extract, carrageenan, characterized in that the composition further comprises an amount of 8-12% of one or more auxiliary ingredients selected from the group consisting of.
(2) 상기 제1용액이 완전히 용해되었으면 L-카르니틴, 비타민A, 비타민B1, 비타민B2, 비타민B6염산염, 비타민D3, 비타민E, 엽산, 나이아신, 자몽종자추출물을 Hopper를 통해 투입한 후 충분히 용해시키는 단계; (3) 상기 제2용액이 완전히 용해되었으면 카라기난과 구연산을 혼합 후 정수(20℃)에 믹서기를 이용해 용해시킨 후 Hopper를 통해 투입한 후 다시 충분히 용해시키는 단계; (4) 상기 제3용액에 오렌지에센스를 투입하고 5분간 교반하는 단계로 구성되며, 이때 정제수와 조성물의 비율은 80-85% : 15-20% 이 되도록 하고, 조성물의 배합비율은 제2항의 주성분과 보조성분의 배합비율에 따라 배함함을 특징으로 하는 액상 건강식품 조성물 제조방법.(1) Purified water (50 ℃) is added to the mixing tank, and liquid fructose, maltodextrin, shark cartilage extract powder, chicory fiber, polydextrose, vitamin C, orange juice, collagen, calcium gluconate, calcium lactate and fructooligosaccharide , Garcinia cambogia extract, zinc gluconate, sucralose, iron lactate is added through a Hopper to dissolve;
(2) When the first solution is completely dissolved, L-carnitine, vitamin A, vitamin B1, vitamin B2, vitamin B6 hydrochloride, vitamin D3, vitamin E, folic acid, niacin, and grapefruit seed extract are introduced through the Hopper and then completely dissolved. Making a step; (3) if the second solution is completely dissolved, carrageenan and citric acid are mixed and dissolved in a purified water (20 ° C.) using a blender, and then introduced through a Hopper to fully dissolve again; (4) adding orange essence to the third solution and stirring for 5 minutes, wherein the ratio of purified water and the composition is 80-85%: 15-20%, the composition ratio of the composition of claim 2 Liquid health food composition manufacturing method characterized in that it is mixed according to the blending ratio of the main component and the auxiliary component.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180091905A KR20200016608A (en) | 2018-08-07 | 2018-08-07 | The health food composition for regulating weight |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180091905A KR20200016608A (en) | 2018-08-07 | 2018-08-07 | The health food composition for regulating weight |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200016608A true KR20200016608A (en) | 2020-02-17 |
Family
ID=69670610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180091905A KR20200016608A (en) | 2018-08-07 | 2018-08-07 | The health food composition for regulating weight |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200016608A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114145452A (en) * | 2021-12-10 | 2022-03-08 | 青岛圣桐营养食品有限公司 | Full-nutrition formula food for special medical use |
CN114158736A (en) * | 2021-12-10 | 2022-03-11 | 青岛圣桐营养食品有限公司 | Compound vitamin suitable for full-nutrition formula food with special medical application |
CN115067504A (en) * | 2022-06-29 | 2022-09-20 | 医林营海(江苏)营养科技有限公司 | Special medical food for intestinal tract preparation and preparation method thereof |
-
2018
- 2018-08-07 KR KR1020180091905A patent/KR20200016608A/en unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114145452A (en) * | 2021-12-10 | 2022-03-08 | 青岛圣桐营养食品有限公司 | Full-nutrition formula food for special medical use |
CN114158736A (en) * | 2021-12-10 | 2022-03-11 | 青岛圣桐营养食品有限公司 | Compound vitamin suitable for full-nutrition formula food with special medical application |
CN114145452B (en) * | 2021-12-10 | 2022-11-01 | 青岛圣桐营养食品有限公司 | Full-nutrition formula food for special medical use |
CN115067504A (en) * | 2022-06-29 | 2022-09-20 | 医林营海(江苏)营养科技有限公司 | Special medical food for intestinal tract preparation and preparation method thereof |
CN115067504B (en) * | 2022-06-29 | 2024-04-16 | 医林营海(江苏)营养科技有限公司 | Special medical food for intestinal tract preparation and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645385B1 (en) | Composition for anti-obesity | |
TWI332399B (en) | Nutritional composition for controlling blood sugar level | |
US6468962B1 (en) | Nutritional intervention composition for enhancing and extending satiety | |
CN101810223B (en) | Functional milky tea powder and preparation method thereof | |
EP2011500B1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
JP2009511468A5 (en) | ||
TW200812503A (en) | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass | |
JP2006508057A (en) | Nutritional composition comprising non-glucose carbohydrate or pectin and soluble fiber | |
JP2008094754A (en) | Nutrient composition for diabetes or blood sugar control | |
KR20150051020A (en) | Composition For Anti-obesity And Diet | |
KR20070113460A (en) | The health food composition for regulating weight | |
KR20200016608A (en) | The health food composition for regulating weight | |
KR100481379B1 (en) | Food composition for lowering body fat content and improving body composition and method therefor | |
US20100035810A1 (en) | Adiponectin production enhancer | |
JP2008266223A (en) | Formulation for ameliorating excessive sensitivity to cold | |
KR101721145B1 (en) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement | |
JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
JP5281895B2 (en) | Calcium absorption promoter | |
KR100237168B1 (en) | Obesity-controlling health food | |
JP7090849B2 (en) | Liver function improving composition and liver function improving food composition | |
JP2004000171A (en) | Functional food product containing maca | |
KR100815212B1 (en) | Antidiabetic and antiobese mixture of leaf extract of cudrania tricuspidata and digestion-resistant maltodextrin | |
KR100293890B1 (en) | Food composition for control of body weight and blood sugar prepared by using Dong-A Green Juice and its residue | |
KR20060024766A (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood |